Analyst Price Targets — ANRO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 3:27 pm | — | H.C. Wainwright | $55.00 | $33.95 | TheFly | Alto Neuroscience price target raised to $55 from $50 at H.C. Wainwright |
| August 13, 2026 11:11 am | Thomas Shrader | BTIG | $37.00 | $29.18 | TheFly | Alto Neuroscience price target raised to $37 from $28 at BTIG |
| May 27, 2026 10:49 am | Patrick Trucchio | H.C. Wainwright | $50.00 | $21.06 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO) |
| May 18, 2026 11:33 am | — | Robert W. Baird | $36.00 | $22.98 | TheFly | Alto Neuroscience price target lowered to $36 from $38 at Baird |
| May 14, 2026 11:55 am | Laura Chico | Wedbush | $24.00 | $22.85 | TheFly | Alto Neuroscience price target raised to $24 from $21 at Wedbush |
| March 16, 2026 2:56 pm | Andrew Tsai | Jefferies | $35.00 | $24.78 | StreetInsider | Alto Neuroscience (ANRO) PT Raised to $35 at Jefferies |
| February 17, 2026 12:13 pm | Thomas Shrader | BTIG | $28.00 | $16.89 | TheFly | Alto Neuroscience price target raised to $28 from $27 at BTIG |
| October 20, 2025 3:05 pm | — | Robert W. Baird | $16.00 | $11.07 | TheFly | Alto Neuroscience price target raised to $16 from $10 at Baird |
| October 23, 2024 6:24 am | Brian Skorney | Robert W. Baird | $10.00 | $14.53 | StreetInsider | Alto Neuroscience (ANRO) PT Lowered to $10 at Baird |
| June 20, 2024 12:50 pm | Brian Skorney | Robert W. Baird | $32.00 | $11.11 | StreetInsider | Baird on Alto Neuroscience (ANRO): 'Incrementally positive on Phase 2 CIAS initiation' |
Latest News for ANRO
Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have issued a buy recommendation on
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith will continue to lead Alto's finance function and oversee corporate strategy and business…
AWM Investment Company Inc. bought a new position in shares of Alto Neuroscience, Inc. (NYSE: ANRO) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 80,000 shares of the company's stock, valued at approximately $2,111,000. AWM Investment Company Inc. owned approximately 0.23% of
Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $36.99 and last traded at $36.4220, with a volume of 867909 shares traded. The stock had previously closed at $34.28. Analyst Upgrades and Downgrades Several research firms recently
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “The second quarter…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANRO.
U.S. House Trading
No House trades found for ANRO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.